Why the study?
Extended therapy with DOACs is common for unprovoked VTE, but real-world data on dosing decisions and their association with outcomes are limited.
Does reduced-dose DOAC therapy affect recurrent VTE and major bleeding compared to full-dose DOAC therapy in patients with unprovoked VTE on extended therapy?
Population
3749 patients with unprovoked VTE in the RIETE registry who survived 6 months without recurrence or major bleeding
Comparison
Reduced-dose vs full-dose DOACs (rivaroxaban or apixaban)
Design
Registry-based cohort study
Follow-up
Median of 240 days
Key result
The provided text is an instructional guide on how to write and organize a scientific paper and contains no clinical trial data.
Authors
Loading...
Registry data on DOAC dosing in unprovoked VTE should not yet change practice; leaves open optimal selection and outcome associations pending randomized trials.
Does reduced-dose DOAC therapy affect recurrent VTE and major bleeding compared to full-dose DOAC therapy in patients with unprovoked VTE on extended therapy?
In patients on extended DOAC therapy for unprovoked VTE, reduced-dose DOACs were associated with a lower risk of major bleeding compared to full-dose DOACs.
Lorenzo et al. (2026) studied this question. The provided text is an instructional guide on how to write and organize a scientific paper and contains no clinical trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: